Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med Chin    2010, Vol. 4 Issue (3) : 280-284     DOI: 10.1007/s11684-010-0098-2
Polycystic ovary syndrome
Zi-Jiang CHEN(), Yuhua SHI
Center for Reproductive Medicine, Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
Download: PDF(87 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Polycystic ovary syndrome (PCOS) is a common gynecologic endocrinopathy. The pathogenesis of PCOS is associated with both heredity and environment. PCOS has adverse impacts on female endocrine, reproduction, and metabolism. PCOS can impact women’s reproductive health, leading to anovulatory infertility and higher rate of early pregnancy loss. PCOS has additional metabolic derangements, such as insulin resistance, impaired glucose tolerance, and dyslipidemia. The risks of diabetes, cardiovascular disease, hypertension, metabolic syndrome, and endometrial cancer among PCOS patients are significantly increased as well.

Keywords polycystic ovary syndrome      genetics      metabolic disturbance     
Corresponding Authors: CHEN Zi-Jiang,Email:zjchen   
Issue Date: 05 September 2010
URL:     OR
1 Azziz R, Woods K S, Reyna R, Key T J, Knochenhauer E S, Yildiz B O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab , 2004, 89(6): 2745–2749
doi: 10.1210/jc.2003-032046
2 Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod , 2004, 19(1): 41–47
doi: 10.1093/humrep/deh098
3 Chen Z J, Shi Y H, Zhao Y R, Li Y, Tang R, Zhao L X, Chang Z H. Correlation between single nucleotide polymorphism of insulin receptor gene with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi , 2004, 39(9): 582–585 (in Chinese)
4 Wang K, You L, Shi Y, Wang L, Zhang M, Chen Z J. Association of genetic variants of insulin degrading enzyme with metabolic features in women with polycystic ovary syndrome. Fertil Steril , 2008, 90(2): 378–384
doi: 10.1016/j.fertnstert.2007.06.016
5 Zhang N, Shi Y H, Hao C F, Gu H F, Li Y, Zhao Y R, Wang L C, Chen Z J. Association of +45G15G(T/G) and +276(G/T) polymorphisms in the ADIPOQ gene with polycystic ovary syndrome among Han Chinese women. Eur J Endocrinol , 2008, 158(2): 255–260
doi: 10.1530/EJE-07-0576
6 Diao X H, Shi Y H, Gao Q, Wang L C, Tang R, Chen Z J. Relationship between single nucleotide polymorphism-56 of calpain-10 gene and glucose and lipid metabolism in polycystic ovary syndrome patients. Zhonghua Fu Chan Ke Za Zhi , 2008, 43(2): 106–109 (in Chinese)
7 Lee J Y, Lee W J, Hur S E, Lee C M, Sung Y A, Chung H W. 111/121 diplotype of Calpain-10 is associated with the risk of polycystic ovary syndrome in Korean women. Fertil Steril , 2009, 92(2): 830–833
doi: 10.1016/j.fertnstert.2008.06.023
8 Hao C F, Bao H C, Zhang N, Gu H F, Chen Z J. Evaluation of association between the CYP11alpha promoter pentannucleotide (TTTTA)n polymorphism and polycystic ovarian syndrome among Han Chinese women. Neuro Endocrinol Lett , 2009, 30(1): 56–60
9 Van Nieuwerburgh F, Stoop D, Cabri P, Dhont M, Deforce D, De Sutter P. Shorter CAG repeats in the androgen receptor gene may enhance hyperandrogenicity in polycystic ovary syndrome. 2008, 24(12): 669–673
10 Ferk P, Perme M P, Teran N, Gersak K. Androgen receptor gene (CAG)n polymorphism in patients with polycystic ovary syndrome, 2008, 90(3): 860–863
11 Christopoulos P, Mastorakos G, Gazouli M, Deligeoroglou E, Katsikis I, Diamanti-Kandarakis E, Panidis D, Creatsas G. Study of association of IRS-1 and IRS-2 genes polymorphisms with clinical and metabolic features in women with polycystic ovary syndrome. Is there an impact? Gynecol Endocrinol , 2010March9 [Epub ahead of print]
12 Fan P, Liu H W, Wang X S, Zhang F, Song Q, Li Q, Wu H M, Bai H. Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome. Hum Reprod , 2010, 25(5): 1288–1294
doi: 10.1093/humrep/deq047
13 Sproul K, Jones M R, Mathur R, Azziz R, Goodarzi M O. Association study of four key folliculogenesis genes in polycystic ovary syndrome. BJOG , 2010, 117(6): 756–760
14 Vural P, De?irmencio?lu S, Saral N Y, Akgül C. Tumor necrosis factor alpha (-308), interleukin-6 (-174) and interleukin-10 (-1082) gene polymorphisms in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol , 2010, 150(1): 61–65
doi: 10.1016/j.ejogrb.2010.02.010
15 Wang K, Wang L, Zhao Y, Shi Y, Wang L, Chen Z J. No association of the Arg51Gln and Leu72Met polymorphisms of the ghrelin gene and polycystic ovary syndrome. Hum Reprod , 2009, 24(2): 485–490
doi: 10.1093/humrep/den430
16 Zheng Q, Shi Y, Yang Z, Xu X, Wang L, Xue F, Gu H F, Chen Z J. Family-based association study of the MCF 2L2 gene and polycystic ovary syndrome. Gynecol Obstet Invest , 2009, 68(3): 171–173
doi: 10.1159/000231520
17 Ewens K G, Stewart D R, Ankener W, Urbanek M, McAllister J M, Chen C, Baig K M, Parker S C, Margulies E H, Legro R S, Dunaif A, Strauss J F 3rd, Spielman R S. Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab , 2010, 95(5): 2306–2315
doi: 10.1210/jc.2009-2703
18 Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H F, Futterweit W, Janssen O E, Legro R S, Norman R J, Taylor A E, Witchel S F. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril , 2009, 91(2): 456–488
doi: 10.1016/j.fertnstert.2008.06.035
19 Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod , 2009, 24(7): 1548–1555
doi: 10.1093/humrep/dep049
20 Blank S K, McCartney C R, Helm K D, Marshall J C. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. Semin Reprod Med , 2007, 25(5): 352–359
doi: 10.1055/s-2007-984741
21 Homburg R. Pregnancy complications in PCOS. Best Pract Res Clin Endocrinol Metab , 2006, 20(2): 281–292
doi: 10.1016/j.beem.2006.03.009
22 Heijnen E M, Eijkemans M J, Hughes E G, Laven J S, Macklon N S, Fauser B C. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update , 2006, 12(1): 13–21
doi: 10.1093/humupd/dmi036
23 Boomsma C M, Eijkemans M J C, Hughes E G, Visser G H, Fauser B C, Macklon N S. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update , 2006, 12(6): 673–683
doi: 10.1093/humupd/dml036
24 Vrbikova J, Hainer V. Obesity and polycystic ovary syndrome. Obes Facts , 2009, 2(1): 26–35
doi: 10.1159/000194971
25 Cupisti S, Kajaia N, Dittrich R, Duezenli H, W Beckmann M, Mueller A. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol , 2008, 158(5): 711–719
doi: 10.1530/EJE-07-0515
26 Wagenknecht L E, Langefeld C D, Scherzinger A L, Norris J M, Haffner S M, Saad M F, Bergman R N. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes , 2003, 52(10): 2490–2496
doi: 10.2337/diabetes.52.10.2490
27 Glueck C J, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism , 2003, 52(7): 908–915
doi: 10.1016/S0026-0495(03)00104-5
28 Palomba S, Falbo A, Russo T, Orio F, Tolino A, Zullo F. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Hum Reprod , 2010, 25(4): 1005–1013
doi: 10.1093/humrep/dep466
29 Toprak S, Y?nem A, Cakir B, Güler S, Azal O, Ozata M, Corak?i A. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res , 2001, 55(2): 65–70
doi: 10.1159/000049972
30 Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes , 1989, 38(9): 1165–1174
doi: 10.2337/diabetes.38.9.1165
31 Apridonidze T, Essah P A, Iuorno M J, Nestler J E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab , 2005, 90(4): 1929–1935
doi: 10.1210/jc.2004-1045
32 Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin Reprod Med , 2008, 26(1): 39–44
doi: 10.1055/s-2007-992923
33 Rocha M P, Maranh?o R C, Seydell T M, Barcellos C R, Baracat E C, Hayashida S A, Bydlowski S P, Marcondes J A. Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic ovary syndrome. Fertil Steril , 2010, 93(6): 1948–1956
doi: 10.1016/j.fertnstert.2008.12.044
34 Soares E M, Azevedo G D, Gadelha R G, Lemos T M, Maranh?o T M. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertil Steril , 2008, 89(3): 649–655
doi: 10.1016/j.fertnstert.2007.03.081
35 Lo J C, Feigenbaum S L, Yang J, Pressman A R, Selby J V, Go A S. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab , 2006, 91(4): 1357–1363
doi: 10.1210/jc.2005-2430
[1] Tao Wang,Weiping Jia,Cheng Hu. Advancement in genetic variants conferring obesity susceptibility from genome-wide association studies[J]. Front. Med., 2015, 9(2): 146-161.
[2] Ching-Hon Pui. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia[J]. Front. Med., 2015, 9(1): 1-9.
[3] Xuejun Zhang. Exome sequencing greatly expedites the progressive research of Mendelian diseases[J]. Front Med, 2014, 8(1): 42-57.
[4] Xiaohong Duan, Thomas Markello, David Adams, Camilo Toro, Cynthia Tifft, William A. Gahl, Cornelius F. Boerkoel. Cultural differences define diagnosis and genomic medicine practice: implications for undiagnosed diseases program in China[J]. Front Med, 2013, 7(3): 389-394.
[5] Sandy Leung-Kuen Au, Irene Oi-Lin Ng, Chun-Ming Wong. Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins[J]. Front Med, 2013, 7(2): 231-241.
[6] Qingqing Xu, Xi Wu, Yuyu Xiong, Qinghe Xing, Lin He, Shengying Qin. Pharmacogenomics can improve antipsychotic treatment in schizophrenia[J]. Front Med, 2013, 7(2): 180-190.
[7] Xiao-Mei ZHANG, Ming-Zhou GUO, . The value of epigenetic markers in esophageal cancer[J]. Front. Med., 2010, 4(4): 378-384.
[8] Dai-Hai YU PhD, Jian-Feng HUANG MD, Ji-Chun CHEN MS, Jie CAO MS, Shu-Feng CHEN PhD, Dong-Feng GU MD, PhD, for the GenSalt Collaborative Research Group, De-Pei LIU PhD, Lai-Yuan WANG PhD, Jing CHEN MD, MSc, Jiang HE MD, PhD, Cashell E. JAQUISH PhD, Dabeeru C. RAO PhD, Charles GU PhD, James E. HIXSON PhD, Chung-Shiuan CHEN MS8, Paul K. WHELTON MD, MSc9, . Genetic variants in the ADD1 and GNB3 genes and blood pressure response to potassium supplementation[J]. Front. Med., 2010, 4(1): 59-66.
[9] Wei-Li ZHANG MD, PhD, Ru-Tai HUI MD, PhD, . Genetics of ischemic and hemorrhagic stroke in Chinese population[J]. Front. Med., 2010, 4(1): 21-28.
[10] ZOU Qilian, LIN Ying, LIN Xiangquan, CHEN Yuanzhong. Genetics analysis of haptoglobin gene in Fujian Han nationality[J]. Front. Med., 2008, 2(1): 105-107.
Full text